299 related articles for article (PubMed ID: 24064822)
1. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
2. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
3. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
4. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
5. Circumventing resistance to kinase-inhibitor therapy.
Druker BJ
N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
[No Abstract] [Full Text] [Related]
6. 10 years of progress in chronic myelogenous leukemia.
Jabbour E; Mathisen MS; O'Brien S
J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803
[No Abstract] [Full Text] [Related]
7. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
8. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Jabbour E; Kantarjian H; Cortes J
Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
[TBL] [Abstract][Full Text] [Related]
10. Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Savona MR; Saglio G
Acta Haematol; 2013; 130(4):268-78. PubMed ID: 23949495
[TBL] [Abstract][Full Text] [Related]
11. [Management of advanced stage chronic myeloid leukemia].
Takahashi N
Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
[No Abstract] [Full Text] [Related]
12. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Harbaum L; Marx A; Goekkurt E; Schafhausen P; Atanackovic D
Int J Hematol; 2014 Jan; 99(1):91-4. PubMed ID: 24264834
[TBL] [Abstract][Full Text] [Related]
13. [Current diagnostic requirements in chronic myeloid leukemia].
Lion T; Webersinke G; Kastner U; Seger C; Mitterbauer-Hohendanner G; Gastl G
Wien Med Wochenschr; 2013 Nov; 163(21-22):477-94. PubMed ID: 24081749
[TBL] [Abstract][Full Text] [Related]
14. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
15. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
16. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Togasaki-Yoshimoto E; Shono K; Onoda M; Yokota A
Leuk Lymphoma; 2014 Feb; 55(2):453-6. PubMed ID: 23697842
[No Abstract] [Full Text] [Related]
17. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
[TBL] [Abstract][Full Text] [Related]
19. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
20. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Jabbour E; Hochhaus A; Cortes J; La Rosée P; Kantarjian HM
Leukemia; 2010 Jan; 24(1):6-12. PubMed ID: 19798095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
